• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Cardiothorac Vasc Anesth . Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation

tetano

Editor, Senior Moderator
J Cardiothorac Vasc Anesth


. 2020 Sep 4;S1053-0770(20)30862-4.
doi: 10.1053/j.jvca.2020.08.067. Online ahead of print.
Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation


Zhen Guo[SUP] 1 [/SUP], Lin Sun[SUP] 1 [/SUP], Bailing Li[SUP] 2 [/SUP], Rui Tian[SUP] 3 [/SUP], Xiaolin Zhang[SUP] 4 [/SUP], Zhongwei Zhang[SUP] 5 [/SUP], Sean P Clifford[SUP] 6 [/SUP], Yuan Liu[SUP] 7 [/SUP], Jiapeng Huang[SUP] 8 [/SUP], Xin Li[SUP] 9 [/SUP]



Affiliations

Abstract

Objective: To explore special coagulation characteristics and anticoagulation management in extracorporeal membrane oxygenation (ECMO)-assisted patients with coronavirus disease 2019 (COVID-19).
Design: Single-center, retrospective observation of a series of patients.
Participants: Laboratory-confirmed severe COVID-19 patients who received venovenous ECMO support from January 20-May 20, 2020.
Interventions: This study analyzed the anticoagulation management and monitoring strategies, bleeding complications, and thrombotic events during ECMO support.
Measurements and main results: Eight of 667 confirmed COVID-19 patients received venovenous ECMO and had an elevated D-dimer level before and during ECMO support. An ECMO circuit pack (oxygenator and tubing) was replaced a total of 13 times in all 8 patients, and coagulation-related complications included oxygenator thrombosis (7/8), tracheal hemorrhage (5/8), oronasal hemorrhage (3/8), thoracic hemorrhage (3/8), bleeding at puncture sites (4/8), and cannulation site hemorrhage (2/8).
Conclusions: Hypercoagulability and secondary hyperfibrinolysis during ECMO support in COVID-19 patients are common and possibly increase the propensity for thrombotic events and failure of the oxygenator. Currently, there is not enough evidence to support a more aggressive anticoagulation strategy.

Keywords: COVID-19; ECMO; SARS-CoV-2; anticoagulation; coronavirus; extracorporeal membrane oxygenation; severe acute respiratory syndrome coronavirus 2; thrombosis.
 
Back
Top Bottom